We read with interest a recent article in Circulation by Wichter et al 1 on cardiac autonomic dysfunction in Brugada syndrome. The authors demonstrated that regionally reduced iodine-123-metaiodobenzylguanidine ( 123 I-MIBG) uptake in the inferior and septal left ventricular wall was present in 8 (47%) of 17 patients with Brugada syndrome but in none of 10 age-matched control subjects. The study may provide new insight into the pathogenesis and arrhythmogenesis of Brugada syndrome. However, we have some questions concerning other indices of 123 I-MIBG imaging, clinical characteristics of the study patients, and timing of 123 I-MIBG imaging. In normal subjects, regional MIBG uptake may be nonhomogeneous and apparently lower in the inferior and septal wall than in the anterior wall 2 : 80Ϯ11% versus 95Ϯ5% (meanϮSD). 3 Additionally, a heterogeneous 123 I-MIBG distribution in the left ventricle may be a physiological phenomenon mediated by the parasympathetic nerve fibers predominantly located in the inferior wall. Therefore, it is possible that segmental (inferior and septal) reduction of 123 I-MIBG uptake in patients with Brugada syndrome is a normal variant. Cardiac 123 I-MIBG markers that have been used include not only regional uptake heterogeneity but also global myocardial uptake (heart-to-mediastinum ratio) and washout kinetics. Our recent study showed that the heart-to-mediastinum ratio has independent and incremental prognostic value. 4 It seems essential to investigate other indices such as the heart-tomediastinum ratio and washout kinetics in patients with Brugada syndrome.
Response
We appreciate the questions raised by Dr Furuhashi and colleagues. However, most of the issues addressed in their letter have already been discussed in the original article (Discussion section). 1 From our large experience with iodine-123-metaiodobenzylguanidine ( 123 I-MIBG)-imaging (see references 3, 4 and others), we agree that 123 I-MIBG uptake may be inhomogeneous (especially in inferior and septal regions) in controls as well as in disease. This finding may be attributed to inhomogeneous distribution of the regional parasympathetic innervation. However, in the 8/17 patients with Brugada syndrome and abnormal 123 I-MIBG images, the regional uptake in inferior and septal segments was as low as 51.0Ϯ8.6% and 54.8Ϯ10.1%, respectively. 1 This magnitude of abnormal uptake is not consistent with the heterogeneities in control subjects (80Ϯ11% in inferior and septal walls) cited by Furuhashi et al. Therefore, it clearly is not a normal variant but indicates a significant reduction in 123 I-MIBG uptake found only in disease.
In contrast to published data concerning the stability of heart-to-mediastinum ratios and washout measurements, our findings showed a significant variability of heart-tomediastinum ratios and washout measurements highly influenced by the placement of the regions of interest (ROI) and by varying background 123 I-MIBG uptake in the mediastinum. 4 Therefore, we focused on quantifying regional rather than global uptake of 123 I-MIBG in our previous as well as in the present study. 1, 3, 4 Because this approach may potentially miss a homogeneous global reduction of 123 I-MIBG uptake in the myocardium, it may underestimate rather than overestimate the number of patients with innervation defects. However, there is obviously a need for complementary studies on global sympathetic innervation. For this reason, our group previously concentrated on the superior technique of PET using 11 C-HED with absolute quantification (see reference 5 and others) with a future study also planned in Brugada syndrome.
The finding of abnormal 123 I-MIBG uptake (magnitude not reported) in asymptomatic individuals with positive ECG signs but negative sodium channel blocker challenge as reported by Furuhashi et al (unpublished data) may add new aspects to the controversial issue of the diagnostic value of sodium channel blocker provocation in asymptomatic individuals with ECGs suspicious for Brugada syndrome. 123 I-MIBG imaging was performed in the chronic state (Ͼ3 months) after an episode of resuscitation or sustained ventricular tachyarrhythmia in all patients of our study. Therefore, we consider our findings not related to a transient effect in the acute phase after DC shock or ventricular tachycardia. 
